Date: 09-Aug-2019

Patient groups push back against Gileads pricey HIV prevention treatment

LOS ANGELES: Gilead Sciences Inc hopes to soon introduce a pricey new pill to prevent HIV in people at risk of contracting the infection, but the drugmaker faces opposition from an unusual source: patient advocates. Such groups have traditionally lobbied for insurance coverage of newer HIV drugs regardless of expense. But at least three U.S. organizations now question whether Gileadís Descovy would be the best option for most people at risk of exposure.